slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy PowerPoint Presentation
Download Presentation
A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy

Loading in 2 Seconds...

play fullscreen
1 / 1

A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy - PowerPoint PPT Presentation


  • 360 Views
  • Uploaded on

V 2. B  k out  (1+ E  C p ). Q. V 1. NN1731 dose. , ,.. Model predictions (individual) Model predictions (typical subject) o , o ,.. Observations + Mean of observations at time point. NN1731 effect. C p. F 1+2. CL. k out.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy' - benjamin


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

V2

Bkout (1+ ECp)

Q

V1

NN1731 dose

,,..Model predictions (individual)

Model predictions (typical subject)

o,o,.. Observations

+ Mean of observations at time point

NN1731 effect

Cp

F1+2

CL

kout

A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy Male Subjects .
  • Andreas Groth1, Judi Møss2, Tine Møller3, Steen H. Ingwersen11Biomodelling, 2Medical and Science, NovoSeven Key Projects, 3Biostatistics, Novo Nordisk A/S, Copenhagen, Denmark *avg@novonordisk.com

Conclusions

An appreciable dose-concentration-response relationship between NN1731 and F1+2 was expressed in a population PK/PD model. Since F1+2 appearance traces the formation of thrombin, this relationship supports the possibility of using F1+2 as a biomarker for haemostatic agents.

Aims

To explore the potential of prothrombin fragments 1&2 (F1+2) as a biomarker for haemostatic agents with a model of the effects of the FVIIa analogue NN1731.

Background

Haemophilic patients suffer a defect in blood coagulation due to lack of either coagulation factor VIII or IX. In some patients, replacement therapy with the lacking coagulation factor eventually results in the formation of antibodies (inhibitors). Inhibitor patients may be treated with by-passing agents such as activated human coagulation factor FVII (FVIIa, NovoSeven). NN1731 is a FVIIa analogue that in vitro has shown increased activity in stimulating the cleavage of prothrombin to thrombin and F1+2, a key step in the coagulatory pathway1. F1+2 was measured in the first clinical trial with NN1731, a dose escalation trial with 4 dosing arms. NN1731 and F1+2 plasma concentrations were related to NN1731 doses to establish a population PK/PD model treating F1+2 as a PD biomarker.

References

1 E. Persson et al, Proc Natl Acad Sci U S A, 96;13583,2001

A sketch of the pro-coagulatory actions of thrombin, also known as coagulation factor IIa. Thrombin activates several coagulatory proteins and these actions cascade down eventually leading to the formation of cross-linked fibrin (CLIa) which forms the actual blood clot.

Methods

  • Strategy:
  • Develop PK-model from NN1731 plasma concentration data.
  • Develop PD-model from individual post-hoc PK model parameters and F1+2 plasma concentration data.
  • Data source: (3 pre- and 10 post-dose PK samples + 1 pre- and 5 post-dose PD samples)  6 healthy subjects  4 active (non-zero) dose levels. Dose range 5 µg/kg-30 µg/kg
  • Modelling: PK and PD in man was modelled sequentially using NONMEM V with FOCE. Regarding inter-individual variability (i.i.v.) on model parameters, log-normal distributions were tested for significance against the hypotheses of zero i.i.v on that parameter (which is why the geometric, rather than the arithmetic, post-hoc estimate means are displayed on fig. 4).

Results

Figure 1. Structure of PK/PD model

Figure 2. Fit of PK/PD model

PK/PD model parameters

10 g/kg

5 g/kg

The PK/PD model predictions of the F1+2 time profiles for each trial subject as well as for the typical subject are shown along with the observations and their means for each dose level.

V1, V2: central & peripheral volumes of distribution, CL: clearance, Q: intercompartmental clearance, B: baseline F1+2 level, kout: rate constant for F1+2, E: NN1731 efficacy

Values in parenthesis: Coefficients of Variation (CV’s) regarding i.i.v. for each parameter.

30 g/kg

20 g/kg

The resulting PK model was a standard two-compartment model with inter-individual variability (i.i.v.) on CL and V2. The PD model was a linear indirect response model with

the plasma concentration of NN1731 affecting the formation of F1+2 , incorporating i.i.v. on baseline F1+2 levels (B) and the efficacy parameter (E). The F1+2 formation rate at the baseline state Cp=0 equals B kout .

Figure 3. Dose-independence check of PK model

Figure 4. Dose-independence check of PD model

B (pM)

V2 (ml/kg)

E pM/h/(IU/ml)

CL ml/kg//h

NN1731 dose

(µg/kg)

o Individual post-hoc estimates

+ Geometric mean of individual post-hoc estimates

NN1731 dose

(µg/kg)

NN1731 dose

(µg/kg)

NN1731 dose

(µg/kg)

o Individual post-hoc estimates

+ Geometric mean of individual post-hoc estimates

The individual post-hoc parameter estimates in the PD model were also checked for dependence on NN1731 dose. The result is less clear-cut than that of the PK parameters (fig. 3), but since the ranges of values for the lowest and the highest dose are quite similar for the efficacy parameter E, it is concluded that the NN1731 concentration-PD response relationship is well described.

Post-hoc parameter estimates of CL and V2 were checked for dose independence. Such a dependence appears to be absent for both parameters, indicating that the PK model is valid over the studied dose-range.